Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 28, 2022 06:10 ET | Source: Roivant Sciences

Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update

Potential blockbuster VTAMA® (tapinarof) approved by FDA for the treatment of plaque psoriasis at end of May 2022 is the first topical novel chemical entity launched for plaque psoriasis in 25 years;...
June 28, 2022 06:00 ET | Source: Roivant Sciences

Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus

Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral brepocitinib generated statistically significant...
June 15, 2022 16:30 ET | Source: Roivant Sciences

Roivant Sciences to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 on Tuesday, June 28, 2022

Investor call and webcast scheduled for Tuesday, June 28 at 8:00 a.m. EDT BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 15, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV), a...
May 24, 2022 06:00 ET | Source: Roivant Sciences

FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years

- EFFICACY: In the pivotal Phase 3 clinical trial program, VTAMA cream met all primary and secondary endpoints and demonstrated highly statistically significant improvement versus vehicle in Physician...
May 19, 2022 16:30 ET | Source: Roivant Sciences

Roivant to Present at Upcoming Investor Conferences

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) will participate in four upcoming healthcare investor conferences: UBS Global...
May 16, 2022 07:00 ET | Source: Roivant Sciences

Aruvant Announces Oral Presentation at American Society of Gene and Cell Therapy (ASGCT)

ARU-1801 reduced vaso-occlusive events and days in the hospital for patients with severe sickle cell disease MILLBURN, N.J. and BASEL, Switzerland, May 16, 2022 (GLOBE NEWSWIRE) -- Aruvant Sciences...
May 02, 2022 07:00 ET | Source: Roivant Sciences

Roivant Appoints Chief Development Officer and Announces Multiple Collaborations in Targeted Protein Degradation

Dr. Srini Ramanathan has over 20 years of experience in drug development and joins Roivant from Horizon Therapeutics where he built scientific R&D capabilities and teams to advance the company’s...
March 25, 2022 08:01 ET | Source: Roivant Sciences

Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting

Tapinarof demonstrated continued improvements for up to 52 weeks in efficacy outcomes, quality of life measures, and tolerability scores with no associated tachyphylaxisTapinarof was well-tolerated in...
March 11, 2022 16:45 ET | Source: Roivant Sciences

Roivant to Present at Targeted Protein Degradation Conference

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, March 11, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its CEO Matt Gline will present at Guggenheim’s...
February 28, 2022 06:01 ET | Source: Roivant Sciences

Genevant Sciences and Arbutus Biopharma File Patent Infringement Lawsuit Against Moderna

Conference call today at 8:00am ET VANCOUVER, British Columbia and CAMBRIDGE, Mass. and BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery...